Form 4: New Enterprise Associates 17, L.P. Reports Beneficial Ownership Changes in MBX Biosciences, Inc. Following IPO

New Enterprise Associates 17, L.P. reports changes in beneficial ownership of MBX Biosciences, Inc. common stock following the company's initial public offering on September 16, 2024, including conversions of preferred stock and open market purchases.

Summary

• New Enterprise Associates 17, L.P. filed a Form 4 detailing changes in beneficial ownership of MBX Biosciences, Inc. (MBX) common stock.
• The report covers transactions occurring on September 16, 2024, coinciding with MBX Biosciences' initial public offering (IPO).
• Series A and Series B Convertible Preferred Stock held by NEA 17 were automatically converted into common stock immediately prior to the IPO at a conversion ratio of 1-for-12.0221.
• NEA 17 acquired 1,023,103 shares of common stock through the conversion of Series A Preferred Stock.
• NEA 17 acquired 2,091,383 shares of common stock through the conversion of Series B Preferred Stock.
• NEA 17 also purchased 500,000 shares of common stock at a price of $16 per share.
• Following these transactions, NEA 17 directly holds 3,614,486 shares of MBX common stock.
• The filing also notes that NEA Partners 17, L.P., NEA 17 GP, LLC, and individual managers of NEA 17 GP indirectly hold these securities but disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard transactions related to an IPO, with NEA 17 increasing its stake in MBX Biosciences, indicating confidence.

Positives

• NEA 17's increased investment in MBX Biosciences through the conversion of preferred stock and open market purchase signals confidence in the company's future prospects following the IPO.

Future Outlook

The document does not contain specific forward-looking statements regarding MBX Biosciences' future performance.

Industry Context

This filing is a standard regulatory requirement following an IPO, providing transparency into the ownership structure of MBX Biosciences and the investment activity of major shareholders like New Enterprise Associates.

Comparison to Industry Standards

• Form 4 filings are standard practice for significant shareholders following corporate events like IPOs, mergers, or acquisitions.
• The reported transactions are typical for venture capital firms like New Enterprise Associates that often hold preferred stock in companies they invest in prior to an IPO.
• The conversion of preferred stock to common stock is a common mechanism to simplify the capital structure of a company before or during an IPO, similar to what was seen in the IPOs of companies like Moderna and BioNTech.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of MBX Biosciences.
• The increased stake of NEA 17 could be viewed positively by investors, signaling confidence in the company's prospects.

Key Dates